Smith & Nephew Plc (SNN)

35.30
0.10 0.28
NYSE : Health Technology
Prev Close 35.20
Open 35.24
Day Low/High 35.19 / 35.43
52 Wk Low/High 33.79 / 40.43
Volume 200.20K
Avg Volume 551.50K
Exchange NYSE
Shares Outstanding 437.42M
Market Cap 15.39B
EPS 1.80
P/E Ratio N/A
Div & Yield 0.71 (1.91%)

Latest News

UK's NICE Publishes A Medtech Innovation Briefing On PICO™ For The Prophylactic Use In Surgically Closed Incisions To Reduce Surgical Site Complications

UK's NICE Publishes A Medtech Innovation Briefing On PICO™ For The Prophylactic Use In Surgically Closed Incisions To Reduce Surgical Site Complications

LONDON and NEW YORK, July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB)...

Sunniva Inc. Announces Voting Results From Annual General And Special Meeting Of Shareholders

Sunniva Inc. Announces Voting Results From Annual General And Special Meeting Of Shareholders

VANCOUVER, June 29, 2018 /PRNewswire/ - Sunniva Inc. (" Sunniva" or the " Company") ( CSE: SNN) ( OTCQX: SNNVF), a North American provider of cannabis products and services, is pleased to announce the voting results from its Annual General and Special...

Sunniva Inc. Closes Previously Announced Okanagan Falls Property Purchase

Sunniva Inc. Closes Previously Announced Okanagan Falls Property Purchase

VANCOUVER, June 18, 2018 /PRNewswire/ - Sunniva Inc. (" Sunniva" or the " Company") ( CSE: SNN) ( OTCQX:SNNVF), a North American provider of cannabis products and services, is pleased to announce that its wholly-owned subsidiary, Sunniva Medical Inc.

Here's How Medtronic Can Unlock Shareholder Value, Says Analyst

Here's How Medtronic Can Unlock Shareholder Value, Says Analyst

The appointment of Mike Weinstein as senior vice president of strategy has sparked the question of what the med tech firm should do to unlock shareholder value.

First Week Of SNN December 21st Options Trading

Investors in Smith & Nephew plc saw new options begin trading this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

IIROC Trade Resumption - SNN

IIROC Trade Resumption - SNN

IIROC Trading Halt - SNN

IIROC Trading Halt - SNN

IIROC Trade Resumption - SNN

IIROC Trade Resumption - SNN

IIROC Trading Halt - SNN

IIROC Trading Halt - SNN

Smith & Nephew: RCT Demonstrates A 71% Reduction In The Onset Of Sacral Pressure Ulcers When Adding ALLEVYN¿ LIFE To Standard Preventative Protocol

Smith & Nephew: RCT Demonstrates A 71% Reduction In The Onset Of Sacral Pressure Ulcers When Adding ALLEVYN¿ LIFE To Standard Preventative Protocol

Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew's...

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activist investors have helped smaller shareholders win higher valuations for their holdings.

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Paul Singer's Elliott is said to have started building a stake in the maker of artificial hips and knees, sending shares higher.

Cramer: Don't Fear the Activist

Cramer: Don't Fear the Activist

Their involvement can boost a company's stock.

Study Results Demonstrate 74% Reduction In Surgical Site Infections With Use Of PICO™ Single Use Negative Pressure Wound Therapy System

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, proudly supports results of an independent, randomised clinical trial 1 concluding that, in the patients studied, the use of the PICO Single Use...

European Stocks Rise but London Blue Chips Slip on Stronger Pound

European Stocks Rise but London Blue Chips Slip on Stronger Pound

The FTSE 100 lagged its counterparts on Thursday following a run of broker downgrades and after a stronger pound ate into FX gains for London's blue chips.

Take Advantage of U.K. Budget to Bag Some Bargains

Take Advantage of U.K. Budget to Bag Some Bargains

Investors should look at cheap, inflation-proof stocks, which could be very cheap.

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

When interest rates rise, these quality dividend growth stocks should weather the storm.

Smith & Nephew Reinforces Strong Educational Commitment To Advanced Wound Management At World Union Of Wound Healing Societies Meeting (WUWHS)

Smith & Nephew Reinforces Strong Educational Commitment To Advanced Wound Management At World Union Of Wound Healing Societies Meeting (WUWHS)

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, highlights three scientific symposia at World Union of Wound Health Societies (WUWHS) on 25-29 September 2016 in Florence, Italy.

Perrenial Target and Acquirer NuVasive Names New President and COO

Perrenial Target and Acquirer NuVasive Names New President and COO

The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.

New Protocol Including The Use Of ALLEVYN™ LIFE Reduces Hospital-acquired Pressure Ulcers By 69% In Large Facility

New Protocol Including The Use Of ALLEVYN™ LIFE Reduces Hospital-acquired Pressure Ulcers By 69% In Large Facility

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, announces the publication of a new research paper showing how a comprehensive ulcer prevention programme which included the use of...

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.

Rival Offer for LDR Is Unlikely, but Never Say Never

Rival Offer for LDR Is Unlikely, but Never Say Never

The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.